Literature DB >> 22698489

Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study.

Marianne Benn1, Anne Tybjaerg-Hansen, Mark I McCarthy, Gorm B Jensen, Peer Grande, Børge G Nordestgaard.   

Abstract

OBJECTIVES: The purpose of this study was to test whether elevated nonfasting glucose levels associate with and cause ischemic heart disease (IHD) and myocardial infarction (MI).
BACKGROUND: Elevated fasting plasma glucose levels associate with increased risk of IHD, but whether this is also true for nonfasting levels and whether this is a causal relationship is unknown.
METHODS: Using a Mendelian randomization approach, we studied 80,522 persons from Copenhagen, Denmark. Of those, IHD developed in 14,155, and MI developed in 6,257. Subjects were genotyped for variants in GCK (rs4607517), G6PC2 (rs560887), ADCY5 (rs11708067), DGKB (rs2191349), and ADRA2A (rs10885122) associated with elevated fasting glucose levels in genome-wide association studies.
RESULTS: Risk of IHD and MI increased stepwise with increasing nonfasting glucose levels. The hazard ratio for IHD in subjects with nonfasting glucose levels ≥11 mmol/l (≥198 mg/dl) versus <5 mmol/l (<90 mg/dl) was 6.9 (95% confidence interval [CI]: 4.2 to 11.2) adjusted for age and sex, and 2.3 (95% CI: 1.3 to 4.2) adjusted multifactorially; corresponding values for MI were 9.2 (95% CI: 4.6 to 18.2) and 4.8 (95% CI: 2.1 to 11.2). Increasing number of glucose-increasing alleles was associated with increasing nonfasting glucose levels and with increased risk of IHD and MI. The estimated causal odds ratio for IHD and MI by instrumental variable analysis for a 1-mmol/l (18-mg/dl) increase in nonfasting glucose levels due to genotypes combined were 1.25 (95% CI: 1.03 to 1.52) and 1.69 (95% CI: 1.28 to 2.23), and the corresponding observed hazard ratio for IHD and MI by Cox regression was 1.18 (95% CI: 1.15 to 1.22) and 1.09 (95% CI: 1.07 to 1.11), respectively.
CONCLUSIONS: Like common nonfasting glucose elevation, plasma glucose-increasing polymorphisms associate with increased risk of IHD and MI. These data are compatible with a causal association.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698489      PMCID: PMC4606982          DOI: 10.1016/j.jacc.2012.02.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

1.  AAHA diabetes management guidelines.

Authors:  Renee Rucinsky; Audrey Cook; Steve Haley; Richard Nelson; Debra L Zoran; Melanie Poundstone
Journal:  J Am Anim Hosp Assoc       Date:  2010 May-Jun       Impact factor: 1.023

2.  Universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Harvey D White
Journal:  J Am Coll Cardiol       Date:  2007-11-27       Impact factor: 24.094

3.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

4.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.

Authors:  Ruth Frikke-Schmidt; Børge G Nordestgaard; Maria C A Stene; Amar A Sethi; Alan T Remaley; Peter Schnohr; Peer Grande; Anne Tybjaerg-Hansen
Journal:  JAMA       Date:  2008-06-04       Impact factor: 56.272

5.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

6.  Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis.

Authors:  Benjamin F Voight; Laura J Scott; Valgerdur Steinthorsdottir; Andrew P Morris; Christian Dina; Ryan P Welch; Eleftheria Zeggini; Cornelia Huth; Yurii S Aulchenko; Gudmar Thorleifsson; Laura J McCulloch; Teresa Ferreira; Harald Grallert; Najaf Amin; Guanming Wu; Cristen J Willer; Soumya Raychaudhuri; Steve A McCarroll; Claudia Langenberg; Oliver M Hofmann; Josée Dupuis; Lu Qi; Ayellet V Segrè; Mandy van Hoek; Pau Navarro; Kristin Ardlie; Beverley Balkau; Rafn Benediktsson; Amanda J Bennett; Roza Blagieva; Eric Boerwinkle; Lori L Bonnycastle; Kristina Bengtsson Boström; Bert Bravenboer; Suzannah Bumpstead; Noisël P Burtt; Guillaume Charpentier; Peter S Chines; Marilyn Cornelis; David J Couper; Gabe Crawford; Alex S F Doney; Katherine S Elliott; Amanda L Elliott; Michael R Erdos; Caroline S Fox; Christopher S Franklin; Martha Ganser; Christian Gieger; Niels Grarup; Todd Green; Simon Griffin; Christopher J Groves; Candace Guiducci; Samy Hadjadj; Neelam Hassanali; Christian Herder; Bo Isomaa; Anne U Jackson; Paul R V Johnson; Torben Jørgensen; Wen H L Kao; Norman Klopp; Augustine Kong; Peter Kraft; Johanna Kuusisto; Torsten Lauritzen; Man Li; Aloysius Lieverse; Cecilia M Lindgren; Valeriya Lyssenko; Michel Marre; Thomas Meitinger; Kristian Midthjell; Mario A Morken; Narisu Narisu; Peter Nilsson; Katharine R Owen; Felicity Payne; John R B Perry; Ann-Kristin Petersen; Carl Platou; Christine Proença; Inga Prokopenko; Wolfgang Rathmann; N William Rayner; Neil R Robertson; Ghislain Rocheleau; Michael Roden; Michael J Sampson; Richa Saxena; Beverley M Shields; Peter Shrader; Gunnar Sigurdsson; Thomas Sparsø; Klaus Strassburger; Heather M Stringham; Qi Sun; Amy J Swift; Barbara Thorand; Jean Tichet; Tiinamaija Tuomi; Rob M van Dam; Timon W van Haeften; Thijs van Herpt; Jana V van Vliet-Ostaptchouk; G Bragi Walters; Michael N Weedon; Cisca Wijmenga; Jacqueline Witteman; Richard N Bergman; Stephane Cauchi; Francis S Collins; Anna L Gloyn; Ulf Gyllensten; Torben Hansen; Winston A Hide; Graham A Hitman; Albert Hofman; David J Hunter; Kristian Hveem; Markku Laakso; Karen L Mohlke; Andrew D Morris; Colin N A Palmer; Peter P Pramstaller; Igor Rudan; Eric Sijbrands; Lincoln D Stein; Jaakko Tuomilehto; Andre Uitterlinden; Mark Walker; Nicholas J Wareham; Richard M Watanabe; Gonçalo R Abecasis; Bernhard O Boehm; Harry Campbell; Mark J Daly; Andrew T Hattersley; Frank B Hu; James B Meigs; James S Pankow; Oluf Pedersen; H-Erich Wichmann; Inês Barroso; Jose C Florez; Timothy M Frayling; Leif Groop; Rob Sladek; Unnur Thorsteinsdottir; James F Wilson; Thomas Illig; Philippe Froguel; Cornelia M van Duijn; Kari Stefansson; David Altshuler; Michael Boehnke; Mark I McCarthy
Journal:  Nat Genet       Date:  2010-07       Impact factor: 38.330

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.

Authors:  Børge G Nordestgaard; Marianne Benn; Peter Schnohr; Anne Tybjaerg-Hansen
Journal:  JAMA       Date:  2007-07-18       Impact factor: 56.272

9.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.

Authors:  R Clarke; M Shipley; S Lewington; L Youngman; R Collins; M Marmot; R Peto
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

10.  Mendelian randomization: using genes as instruments for making causal inferences in epidemiology.

Authors:  Debbie A Lawlor; Roger M Harbord; Jonathan A C Sterne; Nic Timpson; George Davey Smith
Journal:  Stat Med       Date:  2008-04-15       Impact factor: 2.373

View more
  22 in total

1.  Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study.

Authors:  Marie Kim Wium-Andersen; David Dynnes Ørsted; Børge Grønne Nordestgaard
Journal:  Schizophr Bull       Date:  2013-08-31       Impact factor: 9.306

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 3.  Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.

Authors:  Teemu J Niiranen; Ramachandran S Vasan
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-04-25

Review 4.  Dyslipidaemia of diabetes and the intestine.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  World J Diabetes       Date:  2015-07-10

Review 5.  Highlights of the year in JACC 2012.

Authors:  Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-01-22       Impact factor: 24.094

Review 6.  Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease.

Authors:  Mark O Goodarzi; Jerome I Rotter
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 7.  Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.

Authors:  Richard Kones; Umme Rumana
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 8.  Oxidative stress as a mechanism of added sugar-induced cardiovascular disease.

Authors:  Kailash Prasad; Indu Dhar
Journal:  Int J Angiol       Date:  2014-12

9.  Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.

Authors:  Hertzel C Gerstein; Michael E Miller; Faramarz Ismail-Beigi; Joe Largay; Charlotte McDonald; Heather A Lochnan; Gillian L Booth
Journal:  Lancet       Date:  2014-07-31       Impact factor: 79.321

Review 10.  Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease?

Authors:  Markku Laakso
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.